Galectin-3
Galectin-3↓
The answer is duration, not amount — and the evidence forced this correction. A rise in galectin-3 is the correct response to injury; a rise that never comes back down is the disease. Its own reviewers put it exactly this way: it drives fibrogenesis, 'which may favor limitation of inflammation and wound healing, unless the fibrotic process proceeds beyond tissue repair'. Removing it is harmful in some settings and helpful in others, measured in the same review: genetic deficiency delays wound healing and impairs cardiac remodeling after a heart attack, while the same deficiency improves remodeling in other cardiomyopathies and in hypertension — and in aged animals its absence exacerbates hypertrophy and increases fibrosis. It is required elsewhere too: corneal wounds re-epithelialise more slowly without it, bone cell differentiation and biomechanical competence are impaired without it, and knockout animals on a high-fat diet show worse glucose handling, not better. So the target is the chronic elevation, never the protein itself. Lower it when blood levels sit high for years — above roughly 17.8 ng/mL carries a significantly higher risk of death or hospitalization in chronic heart failure, and in two large cohorts the patients whose levels fell below that line did measurably better. Do not lower it during healing, during training adaptation, or on the assumption that less is always better.
In depth
The lectin that macrophages secrete into damaged tissue — it does not start the scarring signal, it keeps the receiver switched on.
What drives it
Calms body-wide inflammation increases it.
Galectin-3 is an inflammation-derived protein, not a constitutive structural one: it is 'secreted by activated macrophages', and 'as a proinflammatory protein, Gal-3 initiates and amplifies acute inflammatory response through the recruitment of macrophages to the injury site and perpetuating a chronic inflammatory state through the induction of proinflammatory pathways' (doi 10.3389/fphar.2025.1528978). The regulation is not simple and the limit is recorded: in vitro, 'IL-1beta and TGF-beta1 suppress macrophage gal3 synthesis' (PMID 26948424) - so this edge is the tissue-level relationship, not a clean single-cytokine one. doi 10.3389/fphar.2025.1528978 · PMID 26948424
Calms inflammation increases it.
The transcriptional route, and it is structural rather than correlative. Verbatim: 'Promoter methylation status of LGALS3, and elements such as CRE motifs, nuclear factor-kappaB (NF-kB) like sites and GC boxes located within the galectin-3 promoter regulate galectin-3 expression' (Theranostics 2018;8:593). NF-kB does not merely correlate with galectin-3 - it has binding sites in the gene's own promoter. Independently, a chromatin study showed the induction is drivable: 'conditional knockout of BRG1 in hepatocytes attenuated induction of galectin-3 expression in several different animal models of liver injury', BRG1 acting through AP-1 at 'the proximal galectin-3 promoter', with DNA demethylation as 'a rate-limiting step' (PMC6901944). This is the lane a blend can actually reach: lowering synthesis rather than mopping up protein. PMC6901944
Blood pressure hormone increases it.
The RAAS route, shown in both directions. Induction: in the Groningen pectin study, 'Ang II induced an upregulation of the markers ANP, Acta1, and also galectin-3/LGALS3 (~16-fold increase; P < 0.01)' (doi 10.1016/j.retram.2021.103321). Dependence: 'Galectin-3 mediates aldosterone-induced vascular fibrosis' (Arterioscler Thromb Vasc Biol 2013;33:67-75), and blocking galectin-3 with modified citrus pectin prevented the cardiac inflammation and fibrosis of aldosterone-salt rats 'whereas Gal-3 blockade did not modify blood pressure levels' (Hypertension 2015;66:767-75). That last clause is the point: this axis drives fibrosis through galectin-3, not through pressure. doi 10.1016/j.retram.2021.103321
Innate immune sensor increases it.
A reciprocal pair - this runs both ways and that is the interesting part. Galectin-3 'was reported as an endogenous paracrine ligand and activator of TLR-4', and the axis through which modified citrus pectin acted was named 'galectin-3/TLR-4/NF-kB/TNF-alpha' (doi 10.3389/fphar.2025.1528978). Because TLR4 activation drives NF-kB, and NF-kB has binding sites in the LGALS3 promoter, TLR4 also sits upstream of galectin-3 - an amplifying circle in which each raises the other. Rodent toxicity model for the pharmacological arm; the promoter architecture is human. doi 10.3389/fphar.2025.1528978
Clears liver fat increases it.
The metabolic trigger. Galectin-3 transcription is induced in hepatocytes 'by treatment with LPS plus free fatty acid (palmitate)' - endotoxin plus saturated fat - and that induction was suppressed by BRG1 depletion and abolished by TET1 silencing (PMC6901944). Separately, 'galectin-3 levels are up-regulated in the liver by a host of different injurious stimuli'. This link connects steatosis, lipogenesis, gut and insulin signaling to galectin-3. PMC6901944
What it drives
It increases Reduces scarring.
The core mechanism, and it is not what people assume. Galectin-3 does not create the fibrosis instruction; it keeps the receiver switched on. Verbatim: 'Galectin-3 has been shown to prolong cell surface residence and thus enhance responsiveness of the TGF-beta receptor (Partridge et al., 2004), which in turn regulates alternative macrophage differentiation into M2 macrophages and myofibroblast activation.' Independently stated for the heart: it 'can regulate the effects of other molecules involved in fibrosis processes, such as cytokines, by retaining their receptors on the surface membrane of the atrial myofibroblast' (PMC8393977). And: 'Galectin-3 stimulates an M2-like phenotype in macrophages, stimulating synthesis of fibroblast-activating mediators, such as IL-10 and TGF-betas'. doi 10.1093/cvr/cvad156 · PMC8393977
It increases Tissue remodeling.
Galectin-3 is 'secreted by activated macrophages in the heart and promotes cardiac fibrosis by activating fibroblasts to produce excessive collagen and scar tissue'. Genetic evidence in both directions: 'galectin-3 knockout mice are protected from developing fibrosis in response to injury, while mice with elevated galectin-3 develop severe fibrotic changes.' Pharmacological confirmation: 'Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis' (Circ Heart Fail 2013;6:107-117). Limit recorded: a pressure-overload study reached the opposite conclusion - 'galectin-3 loss did not affect survival, systolic and diastolic dysfunction, cardiac fibrosis, and cardiomyocyte hypertrophy' and 'galectin-3 is not a critical modulator of cardiac fibrosis' (PMID 26948424). That is transverse aortic constriction, not an injury model, and the two do not measure the same disease. The direction is right but lower is not always better. A cardiac review that separates pathology from physiology states both halves: 'Genetic deficiency of Gal-3 delays wound healing, impairs cardiac remodeling and function after AMI. On the contrary, Gal-3 deficiency shows opposite results with improved remodeling and function in other cardiomyopathies and in hypertension.' And in normal aging: 'genetic absence of Gal-3 in aged mice exacerbates pathological hypertrophy and increases fibrosis, as opposed to reduced fibrosis shown in cardiac disease.' The governing sentence: galectin-3 drives fibrogenesis 'which may favor limitation of inflammation and wound healing, unless the fibrotic process proceeds beyond tissue repair.' The node is now d:'dur' — the harm is the duration, not the protein. PMID 26948424
It increases Matrix-degrading enzymes.
Extracellular matrix turnover is the currency of scarring. In spinal cord injury, inhibiting galectin-3 with TD139 or silencing it with lentiviral shRNA 'effectively mitigated fibrotic scar formation and extracellular matrix deposition within the injured spinal cord, leading to better neurological outcomes and function recovery' (PMC11481377). The route is direct: galectin-3 from infiltrating macrophages is internalized by PDGFR-beta positive fibroblasts, and 'Galectin-3 inhibition result[ed] in reduced PDGFRbeta expression'. This is a mouse crush-injury model with intrathecal dosing; it is not oral supplementation in people. PMC11481377
It reduces Heart & blood pressure.
This is the strongest human signal on this pathway, and it is prognostic rather than interventional. 'Elevated circulating galectin-3 levels predict heart failure events and all-cause mortality', and 'levels above 17.8 ng/mL are associated with significantly increased risk of death OR hospitalization in patients with chronic heart failure'. Galectin-3 is FDA-approved as a prognostic biomarker for heart failure risk assessment (PMC8393977 reviews its cardiology use). The critical distinction, stated plainly: a marker that predicts an outcome is not proof that lowering it changes that outcome. The one randomized human trial of a galectin-3 inhibitor (modified citrus pectin, NCT01960946) was null on collagen markers, echocardiography and vascular function. PMC8393977
It reduces Kidney.
Modified citrus pectin, which binds the galectin-3 carbohydrate recognition domain, 'is protective in experimental nephropathy with modulation of early proliferation and later galectin-3 expression, apoptosis and fibrosis' in folic-acid acute kidney injury (PMC3072992). A specificity control is present and worth the weight: 'Other renal galectins, galectin-1 and -9, were unchanged.' Separately, galectin-3 blockade reduced renal fibrosis in two normotensive models - obese rats and partial ascending-aorta occlusion (PMC5102450). Animal models only; no human renal outcome. PMC3072992
It increases Innate immune sensor.
Galectin-3 acts on innate immunity directly, not only through fibroblasts: it 'was reported as an endogenous paracrine ligand and activator of TLR-4 inducing an inflammatory response (Burguillos et al., 2015)', and the galectin-3/TLR-4/nf-kB/TNF-alpha axis was the mechanism through which modified citrus pectin ameliorated methotrexate-induced liver and lung toxicity (doi 10.3389/fphar.2025.1528978). Rodent toxicity model. A direct contradiction is recorded here rather than omitted: the same protein restrains the same receptor in other settings. Verbatim: 'galectin-3 has been recently shown to restrain the inflammatory response that involves the Toll-like receptor- (TLR-) 2 and 4 and the proinflammatory cytokines interleukin-1-beta and TNF-alpha in macrophages, an effect that contributes to delay the course of Wallerian degeneration in peripheral nerves, and to reduce the susceptibility to endotoxin shock.' These are different endpoints and different models (chemical liver/lung toxicity versus nerve degeneration and endotoxin challenge), so neither refutes the other — but the edge as drawn is the injury-model direction, and the opposite finding exists. doi 10.3389/fphar.2025.1528978
Blends that modulate it
Each blend page names this pathway and carries the study behind its claim.
See it on the map
Open the causal map to follow this pathway upstream and downstream, arrow by arrow, each with its study.